Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**huangqi + danshen** is a combination of two Chinese herbal medicines: *Astragalus mongholicus* (huangqi) and *Salvia miltiorrhiza* (danshen), frequently used in Traditional Chinese Medicine (TCM). This drug pair is primarily employed for cardiovascular indications, including coronary heart disease and chronic kidney disease. Mechanistically, it acts through multiple pathways: huangqi is known for replenishing "Qi" and supporting metabolic regulation, while danshen activates blood circulation and possesses blood-thinning properties. The combination exerts synergistic effects in improving cardiac function, reducing myocardial infarction size, attenuating fibrosis, regulating hyperlipidaemia, reducing blood viscosity, maintaining circulatory system homeostasis, and protecting against kidney injury. These effects are supported by preclinical network pharmacology and metabolomic analyses, indicating action on metabolic pathways such as lipid metabolism, energy metabolism, amino acid metabolism, and NAD⁺ homeostasis[2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huangqi + danshen.